Kintor Pharmaceutical Limited (KNTPF)
OTCMKTS
· Delayed Price · Currency is USD
0.1774
-0.0315 (-15.08%)
At close: Apr 7, 2025
Kintor Pharmaceutical Employees
Kintor Pharmaceutical had 168 employees as of December 31, 2024. The number of employees decreased by 57 or -25.33% compared to the previous year.
Employees
168
Change (1Y)
-57
Growth (1Y)
-25.33%
Revenue / Employee
$4,077
Profits / Employee
-$126,640
Market Cap
67.52M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Northwest Biotherapeutics | 25 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 374 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Kintor Pharmaceutical News
- 1 year ago - Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China - PRNewsWire
- 1 year ago - Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China - PRNewsWire
- 1 year ago - Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA - PRNewsWire
- 2 years ago - Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US - PRNewsWire
- 2 years ago - Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 - PRNewsWire
- 2 years ago - Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound - PRNewsWire